NASDAQ:TCON • US89237H3084
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TRACON PHARMACEUTICALS INC (TCON).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-07-01 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-04-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-21 | JonesTrading | Downgrade | Buy -> Hold |
| 2023-08-15 | Baird | Maintains | Outperform -> Outperform |
| 2023-05-11 | Baird | Maintains | Outperform -> Outperform |
| 2023-05-11 | Maxim Group | Maintains | Buy |
| 2023-03-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-02-23 | Baird | Initiate | Outperform |
| 2021-06-04 | Alliance Global Partners | Initiate | Buy |
| 2021-04-16 | BTIG | Upgrade | Neutral -> Buy |
| 2021-04-01 | Jones Trading | Initiate | Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 346K | -100.00% | 12.045M | -100.00% | 1.19M | 24.676M 1,973.61% | 73.18M 196.56% | 125.81M 71.92% | 178.67M 42.02% | 248.26M 38.95% | 314.46M 26.67% | |
| EBITDA YoY % growth | -28.333M -74.78% | -27.878M 1.61% | -6.884M 75.31% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.347M -74.73% | -27.894M 1.60% | -6.898M 75.27% | -14.933M -116.48% | -17.745M -18.83% | -4.133M 76.71% | 16.427M 497.42% | 71.438M 334.88% | 132.52M 85.50% | 176.1M 32.89% | 231.67M 31.56% | |
| Operating Margin | -8,192.77% | N/A | -57.27% | N/A | -1,491.14% | -16.75% | 22.45% | 56.78% | 74.17% | 70.93% | 73.67% | |
| EPS YoY % growth | -1.69 22.12% | -1.40 17.16% | 10.04 817.14% | -4.26 -142.40% | -2.92 31.39% | 0.04 101.40% | -0.38 -1,025.00% | -0.31 18.92% | N/A | N/A | N/A |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|
| EPS Q2Q % growth | -1.43 -132.61% | -0.41 -107.03% | -1.02 -610.00% |
| Revenue Q2Q % growth | -100.00% | 1.02M | |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.513M -197.69% | -2.758M 23.12% | -4.196M -1,131.03% |
All data in USD
9 analysts have analysed TCON and the average price target is 31.11 USD. This implies a price increase of 2075.52% is expected in the next year compared to the current price of 1.43.
TRACON PHARMACEUTICALS INC (TCON) will report earnings on 2024-08-12, after the market close.
The consensus EPS estimate for the next earnings of TRACON PHARMACEUTICALS INC (TCON) is -1.43 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering TRACON PHARMACEUTICALS INC (TCON) is 9.